Stockscreener 앱 받기
12.26
0.08%
0.010
Amneal Pharmaceuticals Inc 주식(AMRX)의 최신 뉴스
Amneal Pharmaceuticals, Inc. $AMRX Stock Position Increased by BlackBarn Capital Partners LP - MarketBeat
A Look at Amneal Pharmaceuticals’ Valuation as New FDA Generics to Restasis and ProAir HFA Expand Growth Prospects - Sahm
Amneal Pharmaceuticals (NASDAQ:AMRX) Coverage Initiated at Barclays - MarketBeat
Amneal stock rises after FDA approves epinephrine injection By Investing.com - Investing.com Australia
FDA approves Amneal’s epinephrine injection for emergency care By Investing.com - Investing.com Australia
FDA approves Amneal’s epinephrine injection for emergency care - Investing.com
Amneal stock rises after FDA approves epinephrine injection - Investing.com
Amneal Pharmaceuticals Receives FDA Approval for Epinephrine Injection, Expanding Its Injectables Portfolio for Emergency Care - Quiver Quantitative
Amneal (Nasdaq: AMRX) gains FDA OK for epinephrine vials in $118M U.S. market - Stock Titan
JPMorgan Chase & Co. Buys 240,676 Shares of Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Arrowstreet Capital Limited Partnership Sells 96,228 Shares of Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Amneal Pharmaceuticals, Inc. $AMRX Stock Position Lifted by Walleye Capital LLC - MarketBeat
Amneal’s Parkinson’s drug shows positive interim results By Investing.com - Investing.com Nigeria
Amneal Pharmaceuticals Inc Stock Analysis and ForecastFinancial Sector Performance & Outstanding Profit Strategies - earlytimes.in
Amneal receives U.S. FDA approval for albuterol sulfate inhalation aerosol - MSN
Amneal Pharmaceuticals Reports 'Substantial Clinical Benefit' from Crexont in Phase 4 Study - marketscreener.com
Amneal’s Parkinson’s drug shows positive interim results - Investing.com
Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson’s Disease - The Manila Times
Amneal announces positive interim phase 4 Elevate-Pd results with Crexont for Parkinson's disease - marketscreener.com
Will Amneal Pharmaceuticals Inc. stock deliver better than expected guidance2025 Growth vs Value & Weekly Market Pulse Updates - Newser
Amneal (NASDAQ: AMRX) Phase 4 ELEVATE-PD shows CREXONT boosting ‘Good On’ time - Stock Titan
Amneal wins FDA approval for generic albuterol inhaler - World Aerosols
How Amneal Pharmaceuticals Inc. stock compares to market leaders2025 Top Gainers & Consistent Profit Alerts - Newser
How Back-to-Back RESTASIS and PROAIR Generics At Amneal Pharmaceuticals (AMRX) Has Changed Its Investment Story - Yahoo Finance
AT&T sues generic drugmakers over alleged price-fixing scheme - Reuters
FDA approves Amneal’s generic albuterol inhaler By Investing.com - Investing.com Canada
FDA Approval for Generic Restasis Might Change the Case for Investing in Amneal Pharmaceuticals (AMRX) - simplywall.st
Amneal receives FDA approval for Restasis generic - Eyes On Eyecare
FDA Approves Amneal Pharmaceuticals’ Albuterol Sulfate Inhalation Aerosol for Asthma and COPD Treatment - geneonline.com
FDA approves Amneal Pharmaceuticals' cyclosporine ophthalmic emulsion 0.05% - Ophthalmology Times
Amneal Pharmaceuticals Receives US FDA Approval for Albuterol Sulfate Inhalation Aerosol - marketscreener.com
FDA approves Amneal’s generic albuterol inhaler - Investing.com
Amneal Receives U.S. FDA Approval for Albuterol Sulfate Inhalation Aerosol - The Manila Times
Amneal to Participate in Upcoming Investor Conferences - The Manila Times
How institutional buying supports Amneal Pharmaceuticals Inc. stockWeekly Market Summary & Safe Entry Zone Identification - Newser
Amneal announces FDA approval of cyclosporine ophthalmic emulsion 0.05% - TipRanks
FDA approves Amneal’s generic Restasis for dry eye disease By Investing.com - Investing.com Australia
AbbVie (ABBV) Faces New Generic Competition for Restasis - GuruFocus
FDA approves Amneal’s generic Restasis for dry eye disease - Investing.com
Amneal Pharmaceuticals Wins FDA Approval for Generic Restasis, Plans Q1 Rollout - marketscreener.com
Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05% - The Manila Times
Amneal Pharmaceuticals Receives FDA Approval for Cyclosporine Ophthalmic Emulsion 0.05%, Expanding Its Leadership in Complex Ophthalmic Therapies - Quiver Quantitative
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Price Is Right But Growth Is Lacking After Shares Rocket 25% - simplywall.st
Looking at the Narrative for Amneal as Analyst Targets Shift After Recent Milestones - Yahoo Finance
Is Amneal Pharmaceuticals Still an Opportunity After 61% Price Surge in 2025? - Yahoo Finance
Prudential Financial Inc. Sells 65,965 Shares of Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Has $625,000 Stock Holdings in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Amneal Pharmaceuticals, Inc. $AMRX Holdings Lowered by Geode Capital Management LLC - MarketBeat
1.48%
0.09%
자본화:
|
볼륨(24시간):